

Resource Summary Report

Generated by [NIF](#) on Aug 22, 2026

pT/Caggs-NRASV12

RRID:Addgene_20205

Type: Plasmid

Proper Citation

RRID:Addgene_20205

Plasmid Information

URL: <http://www.addgene.org/20205>

Proper Citation: RRID:Addgene_20205

Insert Name: NRas

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:19147555](#)

Vector Backbone Description: Backbone Marker:Ohlfest Lab; Backbone Size:5607; Vector Backbone:colE1/ampR; Vector Types:Transposon; Bacterial Resistance:Ampicillin

Plasmid Name: pT/Caggs-NRASV12

Relevant Mutation: G12V

Record Creation Time: 20220422T222050+0000

Record Last Update: 20260815T081152+0000

Ratings and Alerts

No rating or validation information has been found for pT/Caggs-NRASV12.

No alerts have been found for pT/Caggs-NRASV12.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jia Y, et al. (2026) SPACE-seq integrates spatial transcriptomics and lineage tracing in native tissues. *Cell stem cell*.

McClellan BL, et al. (2026) Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy. *Molecular therapy. Oncology*, 34(2), 201215.

Zhang S, et al. (2026) Nebivolol Inhibits Hepatocellular Carcinoma via RHOQ and Enhances the Efficacy of Lenvatinib. *International journal of biological sciences*, 22(7), 3617.

Ogawa M, et al. (2026) FGF21 suppresses hepatocellular carcinoma by driving competitive cell-cell interactions. *Cell reports*, 45(6), 117410.

Maggiore G, et al. (2025) Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAs. *Disease models & mechanisms*, 18(8).

Ye L, et al. (2025) Nuclear-localized HKDC1 promotes hepatocellular carcinoma through phosphorylating RBBP5 to upregulate H3K4me3. *Cell reports*, 44(2), 115250.

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.

Tian W, et al. (2025) GCDH Acetylation Orchestrates DNA Damage Response and Autophagy via Mitochondrial ROS to Suppress Hepatocellular Carcinoma Progression. *Research (Washington, D.C.)*, 8, 0862.

Gu L, et al. (2025) FBP1 controls liver cancer evolution from senescent MASH hepatocytes. *Nature*, 637(8045), 461.

Shi G, et al. (2025) GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma. *Cell communication and signaling : CCS*, 23(1), 440.

Wang S, et al. (2025) The Role of the Hexosamine-Sialic Acid Metabolic Pathway Mediated by GFPT1/NANS in c-Myc-Driven Hepatocellular Carcinoma. *Cellular and molecular gastroenterology and hepatology*, 19(9), 101523.

Tao J, et al. (2025) Generation of a spontaneous murine HPV + oral cancer model with site-specific oncogene insertion using CRISPR-SONIC. *Cell & bioscience*, 15(1), 84.

Tay RE, et al. (2025) Serotonin receptor 5-HT2A as a potential target for HCC immunotherapy. *Journal for immunotherapy of cancer*, 13(6).

Yuan S, et al. (2025) VDAC2 loss elicits tumour destruction and inflammation for cancer therapy. *Nature*, 640(8060), 1062.

Cheng Y, et al. (2024) A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence. *Cell*, 187(17), 4770.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Odawara T, et al. (2024) Apoptosis signal-regulating kinase 1 promotes inflammation in senescence and aging. *Communications biology*, 7(1), 691.

Peng H, et al. (2022) N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. *Nature metabolism*, 4(8), 1041.

Haase S, et al. (2022) H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. *The Journal of clinical investigation*, 132(22).

Lo CF, et al. (2022) Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate. *Journal of medicinal chemistry*, 65(19), 12802.